Video

How New Regulatory Requirements for Controlled Substances Are Changing Pharmacists' Daily Practice

Karen Ryle, MS, RPh, associate chief of pharmacy at Massachusetts General Hospital, discusses how the new regulatory requirements for controlled substances are changing pharmacists' daily practice.

Karen Ryle, MS, RPh, associate chief of pharmacy at Massachusetts General Hospital, discusses how the new regulatory requirements for controlled substances are changing pharmacists' daily practice.

This interview was recorded at the ASHP 2014 Midyear Clinical Meeting in Anaheim, California.

Related Videos
Image credit: JJAVA | stock.adobe.com
Related Content
Parent giving their child an antibiotic -- Image credit: Halfpoint | stock.adobe.com
April 21st 2025

Antibiotic Use in Infants and Young Children May Increase Risk of Allergic Conditions

Gillian McGovern, Associate Editor
Pharmacy Focus: Integrating SBIRT in Pharmacies to Combat Substance Use Disorder
March 31st 2025

Pharmacy Focus: Integrating SBIRT in Pharmacies to Combat Substance Use Disorder

Luke Halpern, Assistant Editor
Mother holding baby's foot with measles spots | Image Credit: © rostock-studio - stock.adobe.com
Published: April 18th 2025 | Updated: April 21st 2025

Measles Cases Climb to 800 in United States as Outbreak Spreads Across Borders

Alexandra Gerlach, Associate Editor
Pharmacy Focus: Pharmacists' Role in Medical Cannabis Counseling and Patient Education
February 28th 2025

Pharmacy Focus: Pharmacists' Role in Medical Cannabis Counseling and Patient Education

Luke Halpern, Assistant Editor Jill Simonian, PharmD Codi Peterson, PharmD, MS
Ozempic Insulin injection pen for diabetics. Concept of losing weight with the drug Image credit: Kassandra | stock.adobe.com
April 18th 2025

Study: Vision Impairment Signals Linked to Semaglutide Use

Kennedy Ferruggia, Assistant Editor
People scratch the itch with hand, Elbow, itching, Healthcare And Medicine, Men with skin problem concept
Published: April 18th 2025 | Updated: April 18th 2025

FDA Approves Dupilumab, Marking First Targeted Therapy in a Decade for Chronic Spontaneous Urticaria

Luke Halpern, Assistant Editor